FRANCE – LinKinVax, a Paris, France-based clinical-stage biotechnology company, raised €7.3M in funding.
The round was led by André-Jacques Auberton-Hervé and In-Q-Tel.The company intends to use the funds to accelerate the clinical development of its innovative protein-based vaccine platform.Led by CEO André-Jacques Auberton-Hervé and Prof. Yves Levy, LinKinVax is developing an innovative protein-based vaccine platform that can accelerate availability of vaccines by leveraging the research conducted at the Vaccine Research Institute (VRI). This DC Targeting-based protein vaccine platform can adapt to changes and mutations in the target pathogens. LinKinVax’s technology directly targets dendritic cells (“DC”), which play a crucial role in the immune system, stimulating and regulating immune responses. It is predicated on work by the Vaccine Research Institute/Inserm (VRI) in which Inserm, University of Paris Est Créteil (UPEC), and the Mondor Institute of Biomedical Research (IMRB) participate. This investment contributes to a first capital funding supporting LinKinVax next series A round up to €50 M. 10/01/2023
